The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2017
Filed:
Aug. 13, 2013
Applicant:
Immungene Inc., Thousand Oaks, CA (US);
Inventors:
Assignee:
IMMUNGENE INC, Camarillo, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 38/00 (2006.01); A61K 38/21 (2006.01); C07K 14/57 (2006.01); C07K 14/555 (2006.01); C07K 16/28 (2006.01); C07K 14/56 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
C07K 14/57 (2013.01); C07K 14/555 (2013.01); C07K 14/56 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2833 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 16/2881 (2013.01); C07K 16/2896 (2013.01); C07K 16/40 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01);
Abstract
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell.